 |
PDBsum entry 5eel
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signaling protein/peptide
|
PDB id
|
|
|
|
5eel
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Signaling protein/peptide
|
|
|
Title:
|
|
Grb7 sh2 with bicyclic peptide inhibitor
|
|
Structure:
|
|
Growth factor receptor-bound protein 7. Chain: a, b, c, d, e, f. Fragment: unp rersidues 415-532. Synonym: b47,epidermal growth factor receptor grb-7,grb7 adapter protein. Engineered: yes. Bicyclic peptide inhibitor. Chain: l, m, n, p, q, r. Engineered: yes
|
|
Source:
|
|
Homo sapiens. Human. Organism_taxid: 9606. Gene: grb7. Expressed in: escherichia coli. Expression_system_taxid: 562. Synthetic: yes. Synthetic construct. Organism_taxid: 32630
|
|
Resolution:
|
|
|
2.47Å
|
R-factor:
|
0.188
|
R-free:
|
0.232
|
|
|
Authors:
|
|
G.M.Watson,M.J.Gunzburg,M.C.J.Wilce,J.A.Wilce
|
|
Key ref:
|
|
M.J.Gunzburg
et al.
(2016).
Unexpected involvement of staple leads to redesign of selective bicyclic peptide inhibitor of Grb7.
Sci Rep,
6,
27060.
PubMed id:
DOI:
|
|
|
Date:
|
|
|
23-Oct-15
|
Release date:
|
15-Jun-16
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
Q14451
(GRB7_HUMAN) -
Growth factor receptor-bound protein 7 from Homo sapiens
|
|
|
|
Seq:
Struc:
|
|
|
|
532 a.a.
104 a.a.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key: |
 |
PfamA domain |
|
|
 |
Secondary structure |
|
 |
CATH domain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
Sci Rep
6:27060
(2016)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Unexpected involvement of staple leads to redesign of selective bicyclic peptide inhibitor of Grb7.
|
|
M.J.Gunzburg,
K.Kulkarni,
G.M.Watson,
N.D.Ambaye,
M.P.Del Borgo,
R.Brandt,
S.C.Pero,
P.Perlmutter,
M.C.Wilce,
J.A.Wilce.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
The design of potent and specific peptide inhibitors to therapeutic targets is
of enormous utility for both proof-of-concept studies and for the development of
potential new therapeutics. Grb7 is a key signaling molecule in the progression
of HER2 positive and triple negative breast cancers. Here we report the crystal
structure of a stapled bicyclic peptide inhibitor G7-B1 in complex with the
Grb7-SH2 domain. This revealed an unexpected binding mode of the peptide, in
which the staple forms an alternative contact with the surface of the target
protein. Based on this structural information, we designed a new series of
bicyclic G7 peptides that progressively constrain the starting peptide, to
arrive at the G7-B4 peptide that binds with an approximately 2-fold enhanced
affinity to the Grb7-SH2 domain (KD = 0.83 μM) compared to G7-B1 and
shows low affinity binding to Grb2-, Grb10- and Grb14-SH2 domains
(KD > 100 μM). Furthermore, we determined the structure of the G7-B4
bicyclic peptide in complex with the Grb7-SH2 domain, both before and after ring
closing metathesis to show that the closed staple is essential to the target
interaction. The G7-B4 peptide represents an advance in the development of Grb7
inhibitors and is a classical example of structure aided inhibitor development.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Links
